BIO-TECHNE Corp
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
TECH$72.82-0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Earnings and Comprehensive Income
AND COMPREHENSIVE INCOME
(in thousands, except per share data)
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Quarter Ended · · Nine Months Ended | ||||||||||||
| · · March 31, · · March 31, | ||||||||||||
| · · 2026 · · 2025 · · 2026 · · 2025 | ||||||||||||
| Net sales | | $311,415 | | $316,181 | | $893,847 | | $902,671 | ||||
| Cost of sales | | 103,127 | | 101,625 | | 306,170 | | 311,211 | ||||
| Gross margin | | 208,288 | | 214,556 | | 587,677 | | 591,460 | ||||
| | | | | | | | | | | | | |
| Operating expenses: | | | | | | | | | | | ||
| Selling, general and administrative | | 109,338 | | 151,269 | | 339,242 | | 391,881 | ||||
| Research and development | | 23,455 | | 24,579 | | 70,821 | | 73,464 | ||||
| Total operating expenses | | 132,793 | | 175,848 | | 410,063 | | 465,345 | ||||
| Operating income | | 75,495 | | 38,708 | | 177,614 | | 126,115 | ||||
| | | | | | | | | | | | | |
| Other income (expense) | | (4,270) | | | (434) | | | (7,614) | | | (4,793) | |
| Earnings before income taxes | | 71,225 | | 38,274 | | 170,000 | | 121,322 | ||||
| Income taxes | | 20,178 | | 15,686 | | 42,759 | | 30,244 | ||||
| Net earnings | | $51,047 | | $22,588 | | $127,241 | | $91,078 | ||||
| Other comprehensive income (loss): | | | | | | | | | ||||
| Foreign currency translation income (loss) | | (4,352) | | 5,311 | | (4,440) | | 1,049 | ||||
| Unrealized gains (losses) on derivative instruments | | (160) | | (1,713) | | (2,536) | | (4,785) | ||||
| Other comprehensive income (loss) | | (4,512) | | 3,598 | | (6,976) | | (3,736) | ||||
| Comprehensive income | | $46,535 | | $26,186 | | $120,265 | | $87,342 | ||||
| | | | | | | | | | | | | |
| Earnings per share: | | | | | | | | | | | | |
| Basic | | $0.33 | | $0.14 | | $0.82 | | $0.58 | ||||
| Diluted | | $0.32 | | $0.14 | | $0.81 | | $0.57 | ||||
| | | | | | | | | | | | | |
| Weighted average common shares outstanding: | | | | | | | | | ||||
| Basic | | 156,327 | | 157,372 | | 155,893 | | 158,117 | ||||
| Diluted | | 157,403 | | 158,944 | | 156,943 | | 160,662 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.